Ali J. Satvat

This profile gathers the share dealings of Ali J. Satvat across 3 companies, led by BridgeBio Pharma, Inc., Eidos Therapeutics, Inc. and Coherus Oncology, Inc. We count 11 filings; the first trade dates from 22 June 2018 and the latest from 22 June 2026.

On the market, this insider has only ever bought: 3 purchases, €63.6M in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants and 3 option exercises.

A typical purchase (the median) is worth €23.4M. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 24 June 2026 with a share grant in BridgeBio Pharma, Inc. The most recent open-market purchase was published on 8 July 2019, 2,665 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.